Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists

Abstract

Get full access to this article

View all access options for this article.

References

Statistics Canada. Leading causes of death, by sex (both sexes). Available: www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth36a-eng.htm (accessed July 20, 2014).

Pearson

Thompson

Semchuk

WS.

2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J (Ott) 2007;140:383-8.

Charrois

Zolezzi

Koshman

. A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy 2012;32:222-3.

Anderson

Gregoire

Hegele

. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67.

de Lorgeril

Renaud

Mamelle

. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.

Estruch

Ros

Salas-Salvado

. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90.

Mancini

Tashakkor

Baker

. Diagnosis, prevention and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68.

Richardson

Schoen

French

. Statins and cognitive function: a systematic review. Ann Intern Med 2013;159:688-97.

Joy

Monjed

Zou

. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014;160:301-10.

10.

Sattar

Preiss

Murray

. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.

11.

Preiss

Seshasai

Welsh

. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;22;305:2556-64.

12.

Hovingh

Davidson

Kastelein

O’Connor

AM.

Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013;34:962-71.

13.

Brindle

Beswick

Fahey

Ebrahim

Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752-9.

14.

Lindholm

Carlberg

Samuelsson

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.

15.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

16.

Steg

Bhatt

Wilson

. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.

17.

Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20.

18.

Yeboah

McClelland

Polonsky

. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788-95.

19.

Stone

Robinson

Lichtenstein

. 2013 ACC/AHA guideline for the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934.

20.

Mills

O’Reagan

Eyawo

. Intensive statin therapy compared to moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J 2011;32:1409-15.

21.

Anderson

Gregoire

Hegele

. Are the ACC/AHA guidelines on the treatment of blood cholesterol a game change? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol 2014;30:377-80.

22.

Morris

Ballantyne

Birtcher

. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol 2014;64:196-206.

23.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.

24.

Baigent

Landray

Reith

. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo controlled trial. Lancet 2011;377:2181-92.

25.

Jun

Foote

Neal

Patel

Nicholls

. Effects of fibrates on cardiovascular outcomes: systematic review and meta-analysis. Lancet 2010;375:1875-84.

26.

Ginsberg

Elam

Lovato

, for the ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.

27.

Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.

28.

Canner

Berge

Wenger

. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.

29.

The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2012;365:2255-67.

30.

The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.

31.

Rizos

Ntzani

Bika

. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33.

32.

The Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-8.